IRLAB has received scientific advisory board confirmation on next steps for pirepemat

Gothenburg, Sweden, February 20, 2026. IRLAB Therapeutics (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its scientific advisory board has provided important guidance on the continued development and plans for its drug candidate, pirepemat. The advisory board concludes that the pharmacological rationale for pirepemat is sensible and that the reduction in falls observed in the Phase IIb trial is clinically meaningful, warranting further development.

IRLAB: Invitation to the year-end report 2025 presentation and webcast

IRLAB enters collaboration agreement with Danish biotech company Biomia ApS applying the Integrative Screening Process (ISP)